| P2093 | author name string | Martin Sattler | |
| | Mamatha M Reddy | |
| | Anagha Deshpande | |
| P2860 | cites work | The Janus kinases (Jaks) | Q21194856 |
| | Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control | Q24297854 |
| | HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor | Q24303612 |
| | Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis | Q24316448 |
| | JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin | Q24318979 |
| | Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling | Q24644273 |
| | Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | Q24657681 |
| | The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells | Q24670343 |
| | Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth | Q24685474 |
| | Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 |
| | Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors | Q27619648 |
| | Structural mechanism for STI-571 inhibition of abelson tyrosine kinase | Q27627097 |
| | Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. | Q27851427 |
| | A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms | Q27851467 |
| | Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction | Q28140805 |
| | The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor | Q28214721 |
| | A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo | Q28217482 |
| | The conserved box 1 motif of cytokine receptors is required for association with JAK kinases | Q28236785 |
| | CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients | Q28238474 |
| | Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity | Q28238969 |
| | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 |
| | JAK2 tyrosine kinase phosphorylates PAK1 and regulates PAK1 activity and functions | Q28242536 |
| | Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia | Q28250886 |
| | A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia | Q28253771 |
| | Jak2 is essential for signaling through a variety of cytokine receptors | Q28270987 |
| | Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses | Q28592023 |
| | STATs in cancer inflammation and immunity: a leading role for STAT3 | Q29547203 |
| | Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 |
| | The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes | Q36508949 |
| | Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin | Q37044312 |
| | Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications | Q37204275 |
| | Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells | Q37414714 |
| | Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation | Q37441169 |
| | Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. | Q37460337 |
| | JAK2 gets histone H3 rolling | Q37625023 |
| | How I treat myelofibrosis | Q37825719 |
| | Current and future directions in mammalian target of rapamycin inhibitors development | Q37836904 |
| | New mutations and pathogenesis of myeloproliferative neoplasms. | Q37886439 |
| | Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue | Q39540876 |
| | Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation | Q39575168 |
| | JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation | Q39593309 |
| | Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain | Q39745564 |
| | Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. | Q40024031 |
| | Activated Jak2 with the V617F point mutation promotes G1/S phase transition | Q40288678 |
| | Janus kinases affect thrombopoietin receptor cell surface localization and stability | Q40420997 |
| | Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. | Q41443974 |
| | Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells | Q42554019 |
| | Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia | Q42879211 |
| | Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation | Q43565424 |
| | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 |
| | BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. | Q44155448 |
| | CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth | Q44590668 |
| | Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. | Q44901078 |
| | Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis | Q46230606 |
| | Letter: Bone-marrow responses in polycythemia vera | Q47871256 |
| | Co-expressed complementary fragments of the human red cell anion exchanger (band 3, AE1) generate stilbene disulfonate-sensitive anion transport | Q49056958 |
| | A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. | Q51768323 |
| | Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. | Q54721275 |
| | Enhanced histone deacetylase enzyme activity in primary myelofibrosis. | Q54783682 |
| | Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) | Q77800427 |
| | Myeloproliferative disorders | Q81943280 |
| | Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? | Q29616804 |
| | On respiratory impairment in cancer cells | Q29617276 |
| | Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 |
| | A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 |
| | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 |
| | The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes | Q29619577 |
| | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 |
| | FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 |
| | JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms | Q33383709 |
| | A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms | Q33390255 |
| | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis | Q33393587 |
| | The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors | Q33613105 |
| | STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant | Q33648325 |
| | NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases | Q33834313 |
| | Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors | Q33843072 |
| | CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms | Q33944270 |
| | Identification of an acquired JAK2 mutation in polycythemia vera | Q33947635 |
| | JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective | Q33956483 |
| | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 |
| | Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms | Q34021753 |
| | HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans | Q34162151 |
| | CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis | Q34168482 |
| | Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) [...] | Q34186734 |
| | Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation | Q34245259 |
| | Hsp90: chaperoning signal transduction | Q34319594 |
| | A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient | Q34331384 |
| | The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction | Q34527668 |
| | Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. | Q34541582 |
| | Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies | Q34718163 |
| | The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). | Q34725589 |
| | The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors | Q34754412 |
| | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 |
| | Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway | Q34949540 |
| | The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity | Q35583247 |
| | Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. | Q36003480 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 313-24 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | Targeting JAK2 in the therapy of myeloproliferative neoplasms | |
| P478 | volume | 16 | |